AMARIN CORP PLC\UK Purchase Obligation
AMARIN CORP PLC\UK (AMRN) had Purchase Obligation of $53.00 million as of 2024-09-30, per its 10-Q filed 2024-10-30.
Financial Statements › Notes › Commitment and Contingencies
us-gaap:PurchaseObligation · last filed 2024-10-30
- 2024-09-30: Purchase Obligation $53.00M.
- 2024-06-30: Purchase Obligation $29.00M.
- 2024-03-31: Purchase Obligation $29.00M.
- 2023-12-31: Purchase Obligation $37.00M.
| Period end | Purchase Obligation |
|---|---|
| 2024-09-30 | $53.00M 10-Q · filed 2024-10-30 |
| 2024-06-30 | $29.00M 10-Q · filed 2024-07-31 |
| 2024-03-31 | $29.00M 10-Q · filed 2024-05-01 |
| 2023-12-31 | $37.00M 10-K · filed 2024-02-29 |
| 2023-09-30 | $59.00M 10-Q · filed 2023-11-01 |
| 2023-06-30 | $60.20M 10-Q · filed 2023-08-02 |
| 2023-03-31 | $81.70M 10-Q · filed 2023-05-03 |
| 2022-12-31 | $86.00M 10-K · filed 2023-03-01 |
| 2022-09-30 | $81.50M 10-Q · filed 2022-10-27 |
| 2022-06-30 | $81.50M 10-Q · filed 2022-08-03 |
| 2022-03-31 | $49.30M 10-Q · filed 2022-05-04 |
| 2021-12-31 | $196.10M 10-K · filed 2022-03-01 |
| 2021-09-30 | $213.00M 10-Q · filed 2021-11-03 |
| 2021-06-30 | $213.00M 10-Q · filed 2021-08-05 |
| 2021-03-31 | $213.00M 10-Q · filed 2021-04-29 |
| 2020-12-31 | $326.10M 10-K · filed 2021-02-25 |
| 2020-09-30 | $164.70M 10-Q · filed 2020-11-05 |
| 2020-06-30 | $146.00M 10-Q · filed 2020-08-04 |
| 2020-03-31 | $167.20M 10-Q · filed 2020-04-30 |
| 2019-12-31 | $192.40M 10-K · filed 2020-02-25 |
| 2019-09-30 | $90.00M 10-Q · filed 2019-11-05 |
| 2019-06-30 | $90.00M 10-Q · filed 2019-07-31 |
| 2019-03-31 | $90.00M 10-Q · filed 2019-05-01 |
| 2018-12-31 | $53.00M 10-K · filed 2019-02-27 |
| 2017-12-31 | $40.10M 10-K · filed 2018-02-27 |
| 2016-12-31 | $44.60M 10-K · filed 2017-03-01 |
| 2015-12-31 | $44.70M 10-K · filed 2016-02-25 |
| 2013-03-31 | $5.40M 10-Q · filed 2013-05-09 |
| 2012-12-31 | $9.90M 10-K · filed 2013-02-28 |
| 2012-09-30 | $27.70M 10-Q · filed 2012-11-08 |
| 2012-06-30 | $35.30M 10-Q · filed 2012-08-08 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Processa Pharmaceuticals, Inc. (PCSA) | United States | $0.005B | |
| Dermata Therapeutics, Inc. (DRMA) | United States | $0.005B | -0.62 |
| REVIVA PHARMACEUTICALS HOLDINGS, INC. (RVPH) | United States | $0.005B | |
| Xenetic Biosciences, Inc. (XBIO) | United States | $0.006B | |
| ProPhase Labs, Inc. (PRPH) | United States | $0.006B | -0.06 |
| Cadrenal Therapeutics, Inc. (CVKD) | United States | $0.004B | -0.90 |
| Lakewood-Amedex Biotherapeutics Inc. (LABT) | United States | $0.004B | |
| Pulmatrix, Inc. (PULM) | United States | $0.006B | |
| 60 DEGREES PHARMACEUTICALS, INC. (SXTP) | United States | $0.004B | -0.59 |
| Ernexa Therapeutics Inc. (ERNA) | United States | $0.006B |